Friday, July 18, 2025 7/18/2025

ENHANCING THE IMMUNE RESPONSE TO ANTIGENS DELIVERED BY THE BACTERIAL VECTOR, STRE

Award Number: R43AI072905
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/15/2007
PERIOD OF PERFORMANCE END DATE: 08/31/2009

Group Awards By:

View Award Description

ENHANCING THE IMMUNE RESPONSE TO ANTIGENS DELIVERED BY THE BACTERIAL VECTOR, STRE - DESCRIPTION (provided by applicant): The focus of this proposal is to develop a safe, effective subunit vaccine delivery system. To accomplish this, we will utilize our bacterial commensal vector (BCV) technology. BCV uses the Gram-positive commensal bacteria, Streptococcus gordonii, to express heterologous antigens of interest on its external surface. Phase I human clinical trials indicate that this S. gordonii strain is safe and well-tolerated in humans. Mucosal immunization of mice with S. gordonii expressing vaccinia virus (VV) proteins induced significantly increased vaccinia virus specific antibodies in saliva and serum compared to control animals. Furthermore, serum obtained from immunized mice contained neutralizing antibodies against vaccinia virus. However, immunization of mice with the BCV:VV constructs elicited only partial protection against lethal vaccinia challenge. We hypothesize that co-expression of immunomodulatory molecules by the BCV system will enhance humoral or cellular responses to the encoded antigens, thus providing a safe, effective, and inexpensive subunit vaccine delivery system suitable for use against many viral or bacterial pathogens. To further develop the BCV system the following specific aims are proposed: 1) To enhance the immunogenicity of S. gordonii recombinants by co-expressing cytokines with a model antigen. 2) To evaluate humoral and cellular immune responses to the model antigen after intranasal vaccination of mice with the S. gordonii double recombinants. Public Health Relevance: This Public Health Relevance is not available.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2008 ( Subtotal = $280,538 )
2008	2008	SIGA TECHNOLOGIES, INC	420 LEXINGTON AVENUE	NEW YORK	NY	10170	NEW YORK	USA	Microbiology and Infectious Diseases Research	000	2	7/29/2008	NON-COMPETING CONTINUATION	$280,538
														Subtotal = $280,538

Issue Date FY: 2007 ( Subtotal = $273,956 )
2007	2007	SIGA TECHNOLOGIES, INC	4575 SW RESEARCH WAY SUITE 230	CORVALLIS	OR	97333	BENTON	USA	Microbiology and Infectious Diseases Research	000	1	9/4/2007	NEW	$273,956
														Subtotal = $273,956

Grand Total All Awards = $554,494

Top

All Categories

About

Search

Reports

Data Submission

Award Information

ENHANCING THE IMMUNE RESPONSE TO ANTIGENS DELIVERED BY THE BACTERIAL VECTOR, STRE

Award Number: R43AI072905

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/15/2007

PERIOD OF PERFORMANCE END DATE: 08/31/2009

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer